Preclinical studies have demonstrated that inhibiting these proteins can make cancer cells more susceptible to chemotherapy, modulate the immune response by affecting PD-L1 and IDO1 expression, and induce direct cytotoxic effects. This evidence concerns the gene CD274 and cancer.